Cargando…

Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy

BACKGROUND: Interleukin (IL)-35 is a novel inhibitory cytokine and has recently been implicated in tumor immunity. However, the role of IL-35 in prostate cancer (PCa) has not been elucidated. OBJECTIVE: To evaluate the role of plasma IL-35 in the diagnosis and prognosis of PCa in Chinese patients un...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chenchao, Zhang, Jun, Chen, Ye, Wang, Hao, Hou, Jianquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522820/
https://www.ncbi.nlm.nih.gov/pubmed/28761357
http://dx.doi.org/10.2147/OTT.S135873
_version_ 1783252223380160512
author Zhou, Chenchao
Zhang, Jun
Chen, Ye
Wang, Hao
Hou, Jianquan
author_facet Zhou, Chenchao
Zhang, Jun
Chen, Ye
Wang, Hao
Hou, Jianquan
author_sort Zhou, Chenchao
collection PubMed
description BACKGROUND: Interleukin (IL)-35 is a novel inhibitory cytokine and has recently been implicated in tumor immunity. However, the role of IL-35 in prostate cancer (PCa) has not been elucidated. OBJECTIVE: To evaluate the role of plasma IL-35 in the diagnosis and prognosis of PCa in Chinese patients undergoing initial prostate biopsy. MATERIALS AND METHODS: Using ELISA, plasma IL-35 levels were measured in 180 patients, who underwent a prostate biopsy. The clinical correlation of IL-35 with clinicopathological parameters was also evaluated. Univariate and multivariate logistic regression and receiver operating characteristic (ROC) curve analysis were performed to establish the role of IL-35 as a clinical biomarker. RESULTS: Seventy-five (41.6%) of patients were histopathologically confirmed to have PCa. Plasma IL-35 levels were significantly higher in PCa patients (134.48±78.48 pg/mL) compared to non-PCa patients (67.22±24.08 pg/mL). ROC analysis showed that IL-35 was an independent predictor of PCa. Furthermore, IL-35 was found to be a significantly independent predictor of PCa in a group of patients with prostate-specific antigen levels between 4 and 10 ng/mL; was also able to predict advanced PCa from localized PCa and bone metastasis positive PCa from negative PCa. CONCLUSION: Our data suggest for the first time that plasma IL-35 levels are correlated with PCa and is the independent predictor of PCa progression and metastasis. Thus, IL-35 could be utilized as a potential biomarker for diagnosis and prognosis of PCa, could also aid in decision making and predict the stage of the disease.
format Online
Article
Text
id pubmed-5522820
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55228202017-07-31 Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy Zhou, Chenchao Zhang, Jun Chen, Ye Wang, Hao Hou, Jianquan Onco Targets Ther Original Research BACKGROUND: Interleukin (IL)-35 is a novel inhibitory cytokine and has recently been implicated in tumor immunity. However, the role of IL-35 in prostate cancer (PCa) has not been elucidated. OBJECTIVE: To evaluate the role of plasma IL-35 in the diagnosis and prognosis of PCa in Chinese patients undergoing initial prostate biopsy. MATERIALS AND METHODS: Using ELISA, plasma IL-35 levels were measured in 180 patients, who underwent a prostate biopsy. The clinical correlation of IL-35 with clinicopathological parameters was also evaluated. Univariate and multivariate logistic regression and receiver operating characteristic (ROC) curve analysis were performed to establish the role of IL-35 as a clinical biomarker. RESULTS: Seventy-five (41.6%) of patients were histopathologically confirmed to have PCa. Plasma IL-35 levels were significantly higher in PCa patients (134.48±78.48 pg/mL) compared to non-PCa patients (67.22±24.08 pg/mL). ROC analysis showed that IL-35 was an independent predictor of PCa. Furthermore, IL-35 was found to be a significantly independent predictor of PCa in a group of patients with prostate-specific antigen levels between 4 and 10 ng/mL; was also able to predict advanced PCa from localized PCa and bone metastasis positive PCa from negative PCa. CONCLUSION: Our data suggest for the first time that plasma IL-35 levels are correlated with PCa and is the independent predictor of PCa progression and metastasis. Thus, IL-35 could be utilized as a potential biomarker for diagnosis and prognosis of PCa, could also aid in decision making and predict the stage of the disease. Dove Medical Press 2017-07-14 /pmc/articles/PMC5522820/ /pubmed/28761357 http://dx.doi.org/10.2147/OTT.S135873 Text en © 2017 Zhou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhou, Chenchao
Zhang, Jun
Chen, Ye
Wang, Hao
Hou, Jianquan
Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
title Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
title_full Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
title_fullStr Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
title_full_unstemmed Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
title_short Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
title_sort interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522820/
https://www.ncbi.nlm.nih.gov/pubmed/28761357
http://dx.doi.org/10.2147/OTT.S135873
work_keys_str_mv AT zhouchenchao interleukin35asapredictorofprostatecancerinpatientsundergoinginitialprostatebiopsy
AT zhangjun interleukin35asapredictorofprostatecancerinpatientsundergoinginitialprostatebiopsy
AT chenye interleukin35asapredictorofprostatecancerinpatientsundergoinginitialprostatebiopsy
AT wanghao interleukin35asapredictorofprostatecancerinpatientsundergoinginitialprostatebiopsy
AT houjianquan interleukin35asapredictorofprostatecancerinpatientsundergoinginitialprostatebiopsy